Molecular Imaging Applications

Zaver M. Bhujwalla

JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205. E-mail: zaver@mri.jhu.edu

Highlights
Overview of molecular imaging
MR molecular imaging within the context of other imaging modalities
MR molecular imaging strategies

Target Audience
M.D. and Ph.D. researchers with an interest in molecular imaging concepts and applications.

Introduction
Molecular imaging has revolutionized our perceptions of imaging. This high impact field is finding transformative applications in the understanding, detection, and treatment of nearly all diseases [1].

© *Meiyappan Solaiyappan*

Figure 1: Overview of molecular imaging and its applications

The field of molecular imaging is a an exciting fusion and integration of many different disciplines including molecular biology, chemistry and probe design, imaging technologies, visualization, and image analysis, that are focused on understanding, detecting, and treating oncological, neurological, cardiovascular, inflammatory, metabolic, and infectious diseases (**Figure 1**). Based on their strengths, different imaging modalities provide different but equally valuable information that can be integrated in advancing our understanding of these diseases.

1

As the era of 'omics' progresses towards personalized medicine, the field of molecular imaging is finding multiple uses in noninvasive characterization of the molecular features of diseases and their impact on function. In complex diseases such as cancer, with its tremendous genetic diversity, it is becoming increasingly important to develop molecularly-targeted treatment strategies that combine detection with treatment.

MR molecular imaging within the context of other modalities
A summary of different imaging modalities and their sensitivity, spatial resolution, strengths and weaknesses are presented in **Table 1** [2] and a summary of the different applications of MR techniques are summarized in **Table 2**. These tables highlight the advantages of MR and its strengths in imaging metabolism and physiology. However, a drawback of MR methods is limited sensitivity of detection and several innovative strategies are being pursued to increase these limits.

Table 1: Sensitivity, spatial resolution, and clinical translation of molecular-functional imaging (MFI) modalities [2].

Imaging Modality	Sensitivity of detection in MFI	Spatial Resolution *in vivo*	Advantages	Disadvantages
CT	500 micromolar (Gd-DTPA) – low millimolar (Iodine) range	>10 μm	High spatial resolution	Patients are given high radiation doses
MRI	T_2-contrast, iron oxide nano-particles: nanomolar-micromolar range	4 μm (experimental MRI), 250 μm in plane (clinical MRI)	High spatial resolution	Particle size is often large, which restricts *in vivo* delivery
	T_1 contrast, multilabeled targeted Gd-DTPA macromolecules: >10 μM	4 μm (experimental MRI), 250 μm in plane (clinical MRI)	High spatial resolution	Particle size of contrast agent or reporters is relatively large
MRS	Millimolar range (^{1}H at 4.7 – 11 Tesla)	≥0.5 cm (3 Tesla), 0.7 cm (1.5 Tesla)	Detection of endogenous metabolites	Low sensitivity results in low spatial resolution
Optical	Nanomolar range: ≥50 cells (fluorescence); ≥1000 cells (bioluminescence)	>25 μm, intravital microscopy: 1 – 15 μm	High sensitivity, high spatial resolution	Restricted depth detection
PET	Picomolar range	>1 mm^3 (microPET), ~4-5 mm (clinical PET)	High sensitivity, short-lived isotopes	Low spatial resolution, cyclotron required for generating some isotopes
SPECT	Picomolar range	>1 mm (microSPECT), ≥3 mm (clinical SPECT)	High sensitivity	Low spatial resolution, long-lived isotopes
Ultra-sound	>10^6 microbubbles per ml blood	>40 mm	High spatial resolution, cost effective	Few probes available

Table 2: MR biomarkers currently available for applications in diseases

T_1, T_2, T_2* contrast	• Vascular volume • Permeability surface area product • Extraction fraction • Vessel size • BOLD imaging • Extracellular matrix remodeling • Receptor expression on epithelial and endothelial cells • Enzyme activity dependent contrast • pO_2 • pH

2

Spectroscopic contrast	• Total choline, phosphomonoesters, phosphodiesters • Lactate • Lipid • pH • Energy (ATP, phosphocreatine, inorganic phosphate) • Drug pharmacokinetics • Labeled substrate utilization
Contrast from apparent diffusion coefficient (ADC) of water	• Cell death • Edema • Fiber mapping
Chemical Exchange Saturation Transfer (CEST), Amide proton transfer (APT) contrast	• pH • Receptor expression • Gene expression

Brief outline of molecular imaging strategies

Some of the strategies in molecular imaging are broadly outlined in Figure 2 and include (a) enzyme-based reporters, (b) receptor based reporters, and (c) transporter based reporters [3].


Figure 2: Strategies in molecular imaging (from [3]).

Receptor Expression
Receptors, antigens or proteins expressed on cell surfaces provide available targets for detection and targeting. Labeled antibodies have been used to image antigens overexpressed by cancer cells, such as Her2/neu in breast cancer. MR contrast generated by injecting a biotinylated antibody that binds to a specific receptor, followed by administration of avidin linked to gadolinium-diethylenetriaminepentaacetate (GdDTPA) that binds to the biotin on the antibody [4] can be visualized on T_1-weighted images.

3

Integrins and Angiogenesis
Angiogenesis plays an important role in cancer, stroke and cardiac ischemia. Multiple MR probes have been developed to characterize tumor vasculature. Applications of dynamic contrast enhanced (DCE) MRI based on T_1 or T_2 perfusion probes have dominated the use of MRI in the assessment of vascular parameters, such as perfusion, vascular volume, and permeability surface area product [5]. In recent advances, agents have been developed that bind specifically to receptors expressed on tumor vasculature (reviewed in [6] and [5]).

Cell tracking
Another application of MR probes has been in tracking the migration of stromal and immune cells, by pre-labeling them with gadolinium or iron-based contrast agents [7, 8]. Examples of such studies include detecting the migration and homing of cells involved in tumor progression, such as fibroblasts, natural killer (NK) cells, or stem cells [7-9].

Hypoxia
Several noninvasive MR probes detect hypoxia. *In vivo* imaging of tumor oxygen consumption has been performed using ^{19}F MRSI of ^{19}F oxygen reporters such as 2-nitro-α-[(2,2,2-trifluoroethoxy)methyl]-imidazole-1-ethanol (TF-MISO). TF-MISO is a nitroimidazole-based probe that accumulates in hypoxic cells through a biochemical reduction. The reduced probes bind to endogenous cellular molecules and accumulate in hypoxic cells [10, 11] an can be used to report on hypoxia *in vivo* with ^{19}F MRS [12]. Hypoxic regions are identified by imaging the uptake, distribution and retention of the probes by acquiring ^{19}F MRSI [12] and reviewed in [6].

pH
MRS measurements of tumor pH have identified acidic extracellular and neutral to alkaline intracellular environments in cancer cells and tumors. The chemical shift of the primary intracellular inorganic phosphate (Pi) signal, detected by ^{31}P MRS is pH-dependent and provides a measure of intracellular pH [13]. Exogenous pH markers such as 3-aminopropylphosphonate (3-APP) [14] for ^{31}P MRS or (imidazol-1-yl)3-ethyoxycarbonylpropionic acid (IEPA) [14] or 2-(imidazol-1-yl)succinic acid (ISUCA) for ^{1}H MRSI [15] are used to measure extracellular pH. Relaxation enhanced pH measurements can also be performed *in vivo* using gadolinium-based contrast reagents with a pH-dependent relaxivity pH, such as Gd-DOTA-4AmP^{5-} [16].

Proteolytic activity
Several proteases are involved in cancer invasion and metastases. Several new approaches have been explored to image matrix metalloproteinase (MMP) activity *in vivo* with MRI [17, 18] and reviewed in [6].

CEST
Chemical-exchange-dependent saturation transfer (CEST) can be used for several applications such as measuring pH *in vivo*, detecting exogenous CEST-contrast agents, or detecting amide protons of endogenous mobile cellular proteins and peptides, [19, 20]. CEST reporter proteins can be used for molecular imaging studies in gene promoter and expression studies [21] and in detecting enzyme activity [22].

^{13}C MRS and hyperpolarization
The hyperpolarization of spins significantly increases the sensitivity of detection of the MR signal of ^{13}C-labeled substrates by >10,000. Hyperpolarized ^{13}C-labeled substrates injected systemically, allow real-time metabolic mapping [23-25]. Hyperpolarized ^{13}C has been used to

4

measure *in vivo* pHe, and investigate metabolic pathways and enzymatic activity by labeling different substrates such as pyruvate, glutamate, or fumarate [26-28].

List of References

1. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010;65(7):500-16. PMCID: 3150531.
2. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med. 2007;13(7):287-97.
3. Chao F, Shen Y, Zhang H, Tian M. Multimodality molecular imaging of stem cells therapy for stroke. Biomed Res Int. 2013;2013:849819. PMCID: 3816035.
4. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer research. 2003;63(11):2723-7.
5. Pathak AP, Penet MF, Bhujwalla ZM. MR molecular imaging of tumor vasculature and vascular targets. Adv Genet. 2010;69:1-30.
6. Penet MF, Artemov D, Farahani K, Bhujwalla ZM. MR - eyes for cancer: looking within an impenetrable disease. NMR Biomed. 2013;26(7):745-55. PMCID: 3690531.
7. Granot D, Addadi Y, Kalchenko V, Harmelin A, Kunz-Schughart LA, Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res. 2007;67(19):9180-9.
8. Arbab AS, Janic B, Knight RA, Anderson SA, Pawelczyk E, Rad AM, Read EJ, Pandit SD, Frank JA. Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2008;22(9):3234-46. PMCID: 2518252.
9. Mallett CL, McFadden C, Chen Y, Foster PJ. Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. Cytotherapy. 2012;14(6):743-51.
10. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981;43(4):546-50.
11. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer. 1984;54(11):2441-9.
12. Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB, Matei C, Ling CC, Koutcher JA. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res. 2007;13(12):3738-47.
13. Stubbs M, Bhujwalla ZM, Tozer GM, Rodrigues LM, Maxwell RJ, Morgan R, Howe FA, Griffiths JR. An assessment of 31P MRS as a method of measuring pH in rat tumours. NMR Biomed. 1992;5(6):351-9.
14. van Sluis R, Bhujwalla ZM, Raghunand N, Ballesteros P, Alvarez J, Cerdan S, Galons JP, Gillies RJ. In vivo imaging of extracellular pH using 1H MRSI. Magn Reson Med. 1999;41(4):743-50.
15. Provent P, Benito M, Hiba B, Farion R, Lopez-Larrubia P, Ballesteros P, Remy C, Segebarth C, Cerdan S, Coles JA, Garcia-Martin ML. Serial In vivo Spectroscopic Nuclear Magnetic Resonance Imaging of Lactate and Extracellular pH in Rat Gliomas Shows Redistribution of Protons Away from Sites of Glycolysis. Cancer Res. 2007;67(16):7638-45.
16. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2006;55(2):309-15.

5

17. Lebel R, Jastrzebska B, Therriault H, Cournoyer MM, McIntyre JO, Escher E, Neugebauer W, Paquette B, Lepage M. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2008;60(5):1056-65.

18. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(9):4311-6. PMCID: 2840175.

19. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). Journal of Magnetic Resonance. 2000;143(1):79-87.

20. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nature medicine. 2003;9(8):1085-90.

21. Gilad AA, McMahon MT, Walczak P, Winnard PT, Jr., Raman V, van Laarhoven HW, Skoglund CM, Bulte JW, van Zijl PC. Artificial reporter gene providing MRI contrast based on proton exchange. Nature biotechnology. 2007;25(2):217-9.

22. Yoo B, Sheth VR, Howison CM, Douglas MJ, Pineda CT, Maine EA, Baker AF, Pagel MD. Detection of in vivo enzyme activity with CatalyCEST MRI. Magn Reson Med. 2013. PMCID: 3742626.

23. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003;100(18):10158-63.

24. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A. 2003;100(18):10435-9.

25. Golman K, in 't Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci U S A. 2006;103(30):11270-5.

26. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, Gisselsson A, Nelson SK, Witney TH, Bohndiek SE, Hansson G, Peitersen T, Lerche MH, Brindle KM. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A. 2009;106(47):19801-6.

27. Gallagher FA, Kettunen MI, Day SE, Hu DE, Karlsson M, Gisselsson A, Lerche MH, Brindle KM. Detection of tumor glutamate metabolism in vivo using (13)C magnetic resonance spectroscopy and hyperpolarized [1-(13)C]glutamate. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2011;66(1):18-23.

28. Witney TH, Kettunen MI, Brindle KM. Kinetic modeling of hyperpolarized 13C label exchange between pyruvate and lactate in tumor cells. The Journal of biological chemistry. 2011;286(28):24572-80. PMCID: 3137032.

6

Proc. Intl. Soc. Mag. Reson. Med. 22 (2014)